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Abstract: 
Aim. - Strict glycaemic control has been associated with an increased mortality rate in subjects 
with type 2 diabetes (T2DM). Here we examined platelet function immediately and 24 hours 
following induced hypoglycaemia in people with type 2 diabetes compared to healthy age-
matched controls. 
Methods. - Hyperinsulinaemic clamps reduced blood glucose to 2.8 mmol/L (50mg/dl) for 1 
hour. Sampling at baseline; euglycaemia 5mmol/L (90mg/dl); hypoglycaemia; and at 24 post 
clamp were undertaken. Platelet function was measured by whole blood flow cytometry.  
Results. - 10 subjects with T2DM and 8 controls were recruited. Platelets from people with 
T2DM showed reduced sensitivity to prostacyclin (PGI2, 1nM) following hypoglycaemia. The 
ability of PGI2 to inhibit platelet activation was significantly impaired at 24 hours compared to 
baseline in the T2DM group. Here, inhibition of fibrinogen binding was 29.5% (10.3 – 43.8) 
compared to 50.8% (36.8 – 61.1), (P < 0.05), while inhibition of P-selectin expression was 32% 
(16.1 – 47.6) vs.  54.4% (42.5 – 67.5) (P < 0.05). No significant changes in platelet function 
were noted in controls.  
Conclusion. - Induced hypoglycaemia in T2DM enhances platelet hyperactivity through 
impaired sensitivity to prostacyclin at 24 hours.  
 
Key words: Hypoglycaemia; Platelets; Type 2 diabetes.  
 
Abbreviations: PGI2 = prostacyclin,  
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Introduction:  
Strict glycaemic control is associated with increased risk of hypoglycaemia. Although, 
hypoglycaemia has traditionally been considered a complication of the treatment for type 1 
diabetes, it has recently been recognised as a problem in people with type 2 diabetes (T2DM) 
particularly those on insulin therapy [1]. A lack of cardiovascular benefit with strict glycaemic 
control in recent studies in people with T2DM has raised questions about the role of 
hypoglycaemia in thrombogenesis [2-4].  
Platelets circulate the blood in a quiescent state, maintained by fine balance between 
antithrombotic and prothrombotic molecules synthesised by endothelial cells [5], and play a key 
role in both acute thrombus formation at the site of vascular injury and atherogenesis [5]. 
Endothelial dysfunction, inflammation, oxidative stress, and metabolic alterations may cause 
platelets to be more activated [5]. Studies in people with type 1 diabetes and healthy controls 
report an increase in platelet activation with hypoglycaemia [6, 7]; through mechanisms 
including an elevation in the levels of the counter-regulatory hormone adrenaline [8, 9].  
Activated platelets express P-selectin, released from α-granules, and bind to plasma molecules 
such as fibrinogen. These interactions promote the adhesion of leukocytes to the vessel wall and 
atherosclerosis [5]. Platelet surface expression of P-selectin and fibrinogen binding correlates 
with subsequent cardiac risk [10], and increases in those with cardiovascular disease [11]. Key to 
the inhibition of platelet activation is prostacyclin (PGI2) and nitric oxide [5]. As most studies 
assessing the effects of hypoglycaemia on platelet function and thrombotic risk are conducted in 
people with type 1 diabetes and healthy controls [6-8], their findings may not necessarily be 
applicable to people with T2DM. In this study, we hypothesised that acute hypoglycaemia would 
result in increased platelet activation in T2DM compared to controls, with residual effects at 24 
hours.
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Material and methods: 
Study participants: 
A case-control study was undertaken in people with T2DM and age-matched controls, recruited 
by advert. Study inclusion criteria included non-smoking men and women aged between 40 – 60 
years. Subjects in the normal control group had no medical conditions and were not taking any 
medications. Subjects in the T2DM group had T2DM for less than 10 years and no history of 
microvascular disease (retinopathy, nephropathy, and neuropathy), HbA1C ≤ 9.5% (80.3 
mmol/mol), and were treated with diet or metformin (at least 6-month duration). Exclusion 
criteria included pregnancy, lack of contraception in women of child bearing age, chronic 
medical conditions, use of anti-platelet medications, smoking, drop attacks, alcohol or drug 
abuse, psychiatric illness, or previous history of seizure. All subjects had an ECG to exclude 
overt ischaemia, and venesection to exclude anaemia, hyperlipidaemia, renal or hepatic 
impairment. Subjects in the control group were non-diabetic and had an oral glucose tolerance 
test to excluded diabetes or impaired glucose tolerance. Subjects with diabetes were examined to 
exclude diabetic neuropathy; urine testing to exclude microalbuminuria and retinal screening to 
exclude diabetic retinopathy were undertaken. 
Glucose clamping was performed after a 10 hour fast and all participants were asked to avoid 
exercise, caffeine and alcohol for 24 hours prior to the clamp. Individuals with T2DM stopped 
their metformin two days prior to the visit. Following the clamp subjects were given lunch. 
Twenty-four hours after the clamp, and after a 10 hour fast, subjects attended for venesection 
and an early morning urine sample.  
The study was approved by the Yorkshire and the Humber Research Ethics Committee and all 
study participants gave their signed informed consent. 
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Hyperinsulinaemic euglycaemic-hypoglycaemic clamp studies: 
Three polyethylene catheters were inserted in each antecubital fossa and back of the hand veins 
for blood sampling, insulin/dextrose infusions, and blood glucose measurements, respectively. 
The hand which had the catheter was constantly warmed at 60oC, using a heat box to arterialize 
the veins, and small blood volume withdrawn every 5 minutes from this catheter. The blood was 
analysed instantly for glucose measurement using HemoCue® Glucose 201+ (HemoCue AB, 
Angelholm, Sweden) to guide the rate of the dextrose infusion. The HemoCue’s microcuvettes 
were stored and handled according to the manufacturer’s protocol and the machine was 
calibrated before each session using manufacturer’s control solutions. The HemoCue system 
correlates well with the Yellow Springs Instrument (YSI 2300 STAT), particularly in 
hypoglycaemia [12].  
The insulin infusion rate was constant throughout the clamp at [60mU/body surface area 
(m2)/min], while the rate of the 20% dextrose infusion was adjusted every 5 minutes to achieve 
the target blood glucose level. Body surface area (m2) was calculated as [0.007184 x 
(height(cm)ᶺ0.725) x (weight(kg)ᶺ0.425)] [13]. The duration of the hyperinsulinaemic clamp was 
4 hours and included 4 stages, each lasting 1 hour. In stage 1, the rate of glucose infusion was 
adjusted to achieve a stable blood glucose level of 5 mmol/L (90mg/dl). In stage 2 blood glucose 
was maintained at 5 mmol/L (90mg/dl) for 1 hour (euglycaemic clamp). In stage 3 blood glucose 
level was dropped gradually, over 1 hour, to 2.8 mmol/L (50mg/dl). In stage 4 blood glucose was 
maintained at 2.8 mmol/L (50mg/dl) for 1 hour (hypoglycaemic clamp). 
 
 Biochemical markers: 
Urine samples were collected and aliquots stored at -20°C until batch analysis. Blood samples 
were separated immediately by centrifugation at 2000g for 15 minutes at 4°C, and the aliquots 
were stored at –80°C within 30 minutes of blood taking until batch analysis. Fasting plasma 
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glucose (FPG) was measured using a Synchron LX 20 analyzer (Beckman-Coulter) using the 
manufacturer’s recommended protocol. Total cholesterol, triglycerides, and high-density 
lipoprotein (HDL) cholesterol levels were measured enzymatically using a Synchron LX20 
analyzer (Beckman-Coulter, High Wycombe, UK). Plasma metanephrine and normetanephrine 
were measured by tandem mass spectrometry. The between-run coefficients of variation (CV) 
for the metanephrine and normetanephrine measurements were 6.5–12.2% and 4.7–11.5%, 
respectively.  
 
Platelet function:  
Fluorescein isothiocyanate (FITC)-conjugated anti human CD42b, phycoerythrin (PE)-
conjugated anti human CD62P, PE anti-human CD45, FITC-anti IgG1k, and PE-anti IgG1k 
isotope controls were obtained from BD bioscience (Oxford, UK). FITC-anti human fibrinogen 
was obtained from Dako (Stockport, UK). PGI2 was obtained from Cayman (USA) and 
Adenosine 5′-diphosphate (ADP) from Sigma (Poole, UK).  
 Platelet function was analysed in whole blood by flow cytometry as described previously [14, 
15]. Venous blood was collected without stasis from the antecubital vein into 3.8% sodium 
citrate using a 20-gauge intravenous cannula. The first 2ml of blood was discarded to avoid 
artifactual platelet activation. Samples were prepared within 5 minutes of blood collection. 
For P-selectin expression and fibrinogen binding, 5μL of citrated blood was diluted in 50μL of 
modified Tyrode’s buffer (150mM NaCl, 5mM HEPES [N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid], 0.55mM NaH2PO4, 7mM NaHCO3, 2.7mM KCl, 0.5mM MgCl2, 5.6mM 
glucose, pH 7.4) and mixed with 2μL of FITC anti-CD42b monoclonal antibody, FITC anti-
fibrinogen polyclonal antibody, PE anti-P-selectin monoclonal antibody or IgG isotype control. 
The platelet population was identified by forward and side scatter characteristics and confirmed 
by expression of the platelet specific surface marker CD42b. Fibrinogen binding and P-selectin 
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expression were measured in 10,000 platelet events. To study the sensitivity of platelets to 
activation, diluted blood was stimulated with ADP 0.1 – 10µM and samples were then fixed with 
500μl of 0.2% paraformaldehyde after 10 minutes. In some experiments samples were incubated 
with PGI2 0.1 – 10nM for 2 minutes prior to adding ADP 1µM followed by fixation with 0.2% 
formaldehyde after 10 minutes. Samples were analysed within 3 hours of fixation by flow 
cytometry. P-selectin expression and fibrinogen binding were expressed as the percentage of 
positive platelets above a predefined threshold, which was set at 2% on the appropriate negative 
controls as previously described [15]. 
 
Statistical analysis: 
Baseline demographic data were summarised by the median and interquartile range for 
continuous data; percentages otherwise. Data were checked for normality using Kolmogorov-
Smirnov test. Missing values were excluded on a case wise basis. An area under the curve was 
calculated [16].  Two broad statistical approaches were made (within cases; between T2DM 
cases and controls). Within group comparisons are as follows: changes from baseline at each 
stage (euglycaemia, hypoglycaemia and 24 hours) were compared using the paired t-test (or 
Wilcoxon signed-rank test for non-normally distributed data). Repeated measures were 
compared by analysis of variance (ANOVA) (or Friedman test for non-normally distributed 
data). Between groups’ comparisons are as follows:  for each group (T2DM and controls) a 
difference between baseline and nadir/peak was calculated.  The between group differences were 
compared using the independent t-test (or Mann-Whitney U test for non-normally distributed 
data). A similar approach was made for the area under the curve. Correlations were evaluated 
using Pearson’s coefficient (or Spearman’s coefficient for non-normally distributed data). The 
sample size was too small to adjust for baseline covariates. No subgroup comparisons were 
planned. A two tailed P value of < 0.05 was considered statistically significant. ANOVA post-
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hoc comparisons were presented in two different ways: unadjusted [17] and Sidak test corrected 
for multiple comparisons. Statistical analysis was performed using the PASW statistics 19 
package (SPSS Inc., Chicago, USA).  
 
Results:  
20 participants were screened, 18 recruited (10 people with T2DM, 8 controls). Concomitant use 
of antidepressant medication and an inability to understand the study protocol resulted in 2 
screen failures. In the T2DM group, the median duration of diabetes was 10 months (5 – 24); 
seven participants (70%) were on metformin therapy, while three were diet controlled. 
Participants’ demographics and baseline characteristics are summarised in Table I.  
 
Blood glucose:  
For the control group, target blood glucose achieved was 4.9 ± 0.2 mmol/L (87 ± 3mg/dl) during 
euglycaemia and 2.9 ± 0.1 (52 ± 2mg/dl) mmol/L during hypoglycaemia. For the T2DM group, 
target blood glucose achieved was 4.9 ± 0.2 mmol/L (87 ± 3mg/dl) and 3.0 ± 0.1 mmol/L (54 ± 
2mg/dl) during euglycaemia and hypoglycaemia, respectively.  
 
Platelet function: 
Within each group, there was no significant change in unstimulated, or ADP (0.1 – 10µM) 
stimulated, platelet surface expression of P-selectin or fibrinogen binding during euglycaemia, 
hypoglycaemia or at 24 hours after the clamp (Table S1; see supplementary materials associated 
with this article on line).  
In subjects with T2DM, platelet sensitivity to PGI2 (1nM), measured as percentage inhibition in 
fibrinogen binding and P-selectin expression compared to ADP (1µM), was significantly lower 
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at 24 hours 29.5% (10.3 – 43.8) compared to baseline 50.8% (36.8 – 61.1) for fibrinogen 
binding; and 32.0% (16.1 – 47.6) at 24 hours compared to 54.4% (42.5 – 67.5) at baseline for P-
selectin expression (Table II). Although there was a trend in the T2DM group for a reduction in 
platelet sensitivity to PGI2 0.1nM and 1nM at euglycaemia and hypoglycaemia compared to 
baseline, these changes were not statistically significant when multiple comparisons were 
adjusted for (Table II).  In contrast, in the control group, platelet sensitivity to PGI2 did not 
change acutely during the euglycaemic clamp, hypoglycaemic clamp or at 24 hours afterwards 
(Table II). 
Platelets sensitivity to PGI2 1nM, for both groups combined at baseline and 24 hours, negatively 
correlated with hsCRP levels: rho = -0.318, P = 0.059 for P-selectin expression, rho = -0.396, P 
= 0.017 for fibrinogen binding; and with isoprostane levels: r = -0.51, P < 0.01 for fibrinogen 
binding and r = -0.60, P < 0.01 for P-selectin expression. 
 
Hormonal markers: 
In both groups, plasma metanephrine significantly increased at hypoglycaemic and returned to 
baseline after 24 hours (Table III). There was no significant change in plasma normetanephrine 
during the study in either group. 
 
Discussion: 
In this study platelets sensitivity to PGI2 was significantly impaired at 24 hours after induced 
hypoglycaemia in the T2DM group only. Impaired platelet function was due a dysfunction in the 
inhibitory pathway (sensitivity to PGI2), while the stimulatory pathway (stimulation with ADP) 
remained unaffected, resulting in increased blood coagulability. These results are important as 
platelets play a key role in atherothrombosis [5] and hypoglycaemia is a common complication 
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of strict glycaemic control and insulin therapy in people with T2DM [1]. In a large observational 
study in people with T2DM, strict glycaemic control, with a median HbA1C 6.4% (interquartile 
range 6.1 – 6.6), was associated with increased all-cause and cardiovascular mortality [18]. In 
the ACCORD study, strict glycaemic control in people with T2DM with significantly more 
episodes of severe hypoglycaemia was associated with increased mortality [19]; and although it 
was suggested that hypoglycaemia did not explain the increased mortality rate [20]; no cause for 
the increased deaths has been identified despite further analysis [20-23]. A recent joint position 
statement by the American Diabetes Association (ADA) and the European Association for the 
Study of Diabetes (EASD) stated that “a glucose concentration < 54 mg/dL (3.0 mmol/L) is 
sufficiently low to indicate serious, clinically important hypoglycaemia” [24]. Hypoglycaemia 
may lead to vascular disease through mechanisms including sympatho-adrenal activation and 
catecholamine release, endothelial dysfunction, inflammation, oxidative stress, increased 
coagulation and platelet activation [25]. Our data suggest that an adverse cardiovascular effect of 
hypoglycaemia may persist well beyond the normalisation of blood glucose levels. The fact that 
the observed changes in platelet function in our experiment were only significant with 1nM of 
PGI2 is expected, as the higher dose of PGI2 (10nM) cause maximum inhibition masking small 
changes in platelet function, whilst lower dose of PGI2 (0.1nM) caused minimal inhibition.  
An increase in adrenaline levels with hypoglycaemia has been found to impair platelet function 
in previous studies [8, 26]; however, it is unlikely to fully explain the changes in platelet 
function observed in our study. While metanephrine levels significantly increased in both groups 
at hypoglycaemia in our study, platelets sensitivity to PGI2 at 24 hours was only impaired in the 
T2DM group. Furthermore, any effects of metanephrine are likely to be also observed in the 
absence of PGI2, as adrenaline is known to potentiate the activatory capacity of ADP [9]. 
However, we found that ADP reactivity was similar in all groups suggesting that the observed 
increase in metanephrine does not have a major influence on platelet function under our 
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experimental conditions. Further studies are needed to examine the underlying mechanisms for 
impaired platelet function with hypoglycaemia in people with T2DM. 
A few studies have looked into the effects of acute hypoglycaemia on platelet function using 
either insulin stress test [7] or hyperinsulinaemic hypoglycaemic clamps [6]. These studies were 
mainly performed in people with type 1 diabetes or healthy controls and showed increased 
platelet aggregation [7]; or increased plasma soluble P-selectin levels with acute hypoglycaemia 
[27, 28]. It is worth noting the plasma soluble P-selectin is an indirect measure of platelet 
function and it is also produced by the endothelial cells [29]. Our data are in accord with a study 
of platelet function in people with type 1 diabetes that showed an increase in platelet activation 
after acute hypoglycaemia with a peak at 24 hours, though their data did not reach significance 
[6]. A delayed effect of hypoglycaemia was suggested in a report of impaired autonomic 
function 16 hours after induced hypoglycaemia in healthy men and women [30]. The changes in 
platelet function observed at 24 hours in the T2DM group in our study could be related to an 
increase in inflammation in response to hypoglycaemia [31], or insulin resistance as insulin is 
thought to have an inhibitory effect on platelet activation [32]. The T2DM group in our study 
had a higher BMI and waist circumference compared to controls that may have contributed to 
their impaired platelet function, as obesity is associated with platelet dysfunction probably 
because of increased levels of insulin resistance, inflammation and oxidative stress [33].  
The reduction in platelet sensitivity to PGI2 at 24 hours in the T2DM group in our study could 
also, in theory, be related to insulin. Our data suggest that euglycaemia is associated with 
reduced platelet sensitivity to PGI2 in T2DM but not controls.  This is also evident in the P-
selectin data, although since this is a less sensitive marker the data are not significant.  To the 
best of our knowledge there is no documented evidence that hyperinsulinaemia alters platelet 
cyclic adenosine monophosphate (cAMP) response, and while platelets express the insulin 
receptor [34], little is known of the signalling events it is linked to. However, studies in people 
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with type 1 diabetes and healthy controls have suggested that insulin infusion has either a neutral 
or even a favourable effect on platelet function [6, 35].  
The strengths of this study include the inclusion of a group of people with T2DM, who were 
relatively treatment naïve and not on poly-pharmacy, and an age-matched healthy control group. 
We also examined different markers of platelet function using well-established methods. The 
main study limitation was the small study number. Another limitation is measuring platelet 
function at euglycaemia and hypoglycaemia in the same clamp study, rather than in two separate 
studies, making it difficult for us to exclude an effect for insulin clamp on platelet function. 
However, our study design mimics what happens in a ‘real life’ situation where euglycaemia is 
followed by hypoglycaemia. By comparing platelet function at each time point to the same 
baseline, it reduces the risk of data variability which could be a problem for studies with a small 
sample size [6]. 
In conclusion, induced hypoglycaemia in T2DM enhances blood coagulability through impaired 
platelet sensitivity to prostacyclin at 24 hours. This may lead to increased blood coagulability 
and so enhance the risk for cardiovascular events in this patient group.
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Legends 
Table I. Study participants’ demographics and baseline characteristics. Data presented as 
median (25th/75th centiles). Waist/hip, waist to hip ration; BP, blood pressure; HDL, high 
density lipoprotein; LDL, low density lipoprotein; Chol/HDL, cholesterol to HDL ratio; HbA1C, 
haemoglobin A1C. * P < 0.05. 
 
Table II. Platelet sensitivity to prostacyclin. Whole blood samples were incubated with PGI2 
(0.1 to 10nM) before stimulation with ADP 1µM. Data presented as percentage inhibition of 
fibrinogen and P-selectin expression compared to ADP 1µM only samples (higher numbers 
indicate higher sensitivity to PGI2). Data presented as median (25th/75th centiles). T2DM, type 2 
diabetes mellitus; Fib, fibrinogen binding; PGI2, PGI2; %inhib, percent inhibition. Statistically 
significant changes are highlighted. *P < 0.05 compared to baseline (non-adjusted). ^ P < 0.05 
compared to baseline (post-hoc comparisons Sidak test adjusted). 
 
Table III. A comparison of hormonal markers during insulin clamp. Data presented as 
median (25th/75th centiles). T2DM, type 2 diabetes mellitus; All significant P values are 
highlighted. * P < 0.05 compared to any other time point (non-adjusted). ^ P < 0.05 compared to 
any other time point (post-hoc comparisons Sidak test adjusted). ^^ P < 0.05 compared to 
euglycaemia and 24 hours (post-hoc comparisons Sidak test adjusted). 
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Table I. Study participants’ demographics and baseline characteristics. 
 
 T2DM (n=10) Controls (n=8) 
Age (year) 47.0 (42.0 – 51.5) 47.5 (40.8 – 52.8) 
Males (%) 8 (80%) 5 (62.5%) 
Weight (kg) 103.1 (87.0 – 109.1) 85.5 (71.7 – 99.2) 
BMI (kg/m2) 35.8 (27.3 – 40.9) 28.2 (24.2 – 32.8)* 
Waist circumference 
(cm) 
117.0 (99.5 – 124.7) 91.0 (82.9 – 111.3)* 
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(cm) 
Hips circumference 
(cm) 
113.9 (105.8 – 128.2) 103.0 (99.5 – 113.7) 
Waist/hip 0.99 (0.91 – 1.1) 0.90 (0.83 – 0.98) 
Systolic BP (mmHg) 132 (111 – 142) 123 (116 – 132) 
Diastolic BP (mmHg) 74 (68 – 85) 76 (69 – 82) 
Cholesterol (mmol/L) 5.3 (4.4 – 5.7) 5.6 (4.2 – 5.7) 
Triglycerides (mmol/L) 1.3 (0.98 – 2.2) 1.3 (0.78 – 1.5) 
HDL (mmol/L) 1.2 (0.98 – 1.4) 1.3 (1.2 – 1.3) 
LDL (mmol/L) 3.2 (2.8 – 3.7) 3.5 (2.7 – 3.7) 
Chol/HDL 3.9 (3.6 – 5.8) 4.0 (3.4 – 4.3) 
HbA1C (mmol/mol) 45.5 (39 – 56.3) 34 (31 – 36)* 
HbA1C (%) 6.3 (5.7 – 7.3) 5.3 (5.0 – 5.4)* 
Data presented as median (25th/75th centiles). Waist/hip, waist to hip ration; BP, blood pressure; 
HDL, high density lipoprotein; LDL, low density lipoprotein; Chol/HDL, cholesterol to HDL 
ratio; HbA1C, haemoglobin A1C. * P < 0.05.  
 
Table II. Platelet sensitivity to prostacyclin. 
 Baselin  Euglycaemia Hypoglycaemia 24 hours 
T2DM      
Fib PGI2 10nM  93.9 (70.2 – 95.5) 89.0 (74.1 – 94.8) 89.1 (76.9 – 93.8) 88.7 (84.6 – 93.7) 
Fib PGI2 1nM  50.8 (36.8 – 61.1) 36.5 (12.1 – 51.8)* 29.1 (10.5 – 64.2) 29.5 (10.3 – 43.8)^ 
Fib PGI2 0.1nM 12.5 (3.9 – 15.7) 3.2 (0 – 13.8)* 0.0 (0.0 – 12.9) 7.9 ( 1.6 – 13.3) 
     
P-selectin PGI2 10nM 95.5 (73.5 – 96.4) 90.2 (80.4 – 94.1) 90.7 (76.4 – 93.5) 91.3 (89.8 – 93.4) 
P-selectin PGI2 1nM 54.4 (42.5 – 67.5) 44.2 (16.5 – 60) 36.1 (13.9 – 64.5) 32.0 (16.1 – 47.6)^ 
P-selectin PGI2 0.1nM 18.1 (10.1 – 22.4) 15.3 (0 – 31.7) 4.3 (0 – 19.1) 13.4 (0.9 – 17.4) 
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Controls     
Fib PGI2 10nM  94 (91.1 – 96) 95.7 (91.6 – 96.6) 92 (76 – 95.3) 95.3 (87.6 – 96.4) 
Fib PGI2 1nM 41.8 (19.6 – 80) 43.4 (33.1 – 78.8) 49.9 (31.8 – 56.4) 35.3 (6.1 – 54.5) 
Fib PGI2 0.1nM 8.2 (0.8 – 45.5) 11.6 (1.7 – 30.1) 15.9 (6.5 – 22.3) 5.8 (0.7 – 13.5) 
     
P-selectin PGI2 10nM 90.3 (74.8 – 97.2) 92.4 (83.4 – 93.8) 87.3 (72.7 – 96.3) 95.1 (71.9 – 97) 
P-selectin PGI2 1nM  51.7 (22.1 – 75.7) 46.7 (44.6 – 67.7) 48.4 (31.1 – 65.9) 47.8 (13.3 – 65.5) 
P-selectin PGI2 0.1nM 13.9 (1.7 – 44.2) 15.4 (3.8 – 30.8) 21.3 (7.2 – 22.5) 14.6 (7.1 – 16.0) 
 
Whole blood samples were incubated with PGI2 (0.1 to 10nM) before stimulation with ADP 
1µM. Data presented as percentage inhibition of fibrinogen and P-selectin expression compared 
to ADP 1µM only samples (higher numbers indicate higher sensitivity to PGI2). Data presented 
as median (25th/75th centiles). T2DM, type 2 diabetes mellitus; Fib, fibrinogen binding; PGI2, 
PGI2; %inhib, percent inhibition. * P < 0.05 compared to baseline (non-adjusted). ^ P < 0.05 
compared to baseline (post-hoc comparisons Sidak test adjusted). 
 
Table III. A comparison of hormonal markers during insulin clamp. 
 
 Baseline Euglycaemia Hypoglycaemia 24 hours Comments 
T2DM      
Metanephrine (80 – 510) 
pmol/L 
86 (42 – 
122) 
121 (71 – 
147) 
284 (199 – 
308)*^ 
101 (58 
– 128) 
ANOVA ( P= 
0.001) 
Normetanephrine (120 – 
1180) pmol/L 
153 (127 – 
223) 
143.5 (81 – 
262) 
157 (128 – 282) 202 (133 
– 232) 
 
      
Controls      
Metanephrine (80 – 510) 
pmol/L 
153 (88 – 
225) 
150 (68 – 
222) 
415 (250 – 
607)*^^ 
107 (66 
– 183) 
ANOVA (P = 
0.048) 
Normetanephrine (120 – 
1180) pmol/L 
234 (157 – 
324) 
225 (183 – 
241) 
225 (154 – 358) 231 (177 
– 301) 
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Data presented as median (25th/75th centiles). T2DM, type 2 diabetes mellitus; All significant P 
values are highlighted. * P < 0.05 compared to any other time point (non-adjusted). ^ P < 0.05 
compared to any other time point (post-hoc comparisons Sidak test adjusted). ^^ P < 0.05 
compared to euglycaemia and 24 hours (post-hoc comparisons Sidak test adjusted). 
 
Table S1. Platelet activation and response to stimulation with ADP. 
Group Sample Baseline Euglycaemia Hypoglycaemia 24 hours 
T2DM Fib unstimulated 2.6 (1.8 – 
3.2) 
3.0 (2.3 – 3.6) 2.8 (1.9 – 5.0) 1.9 (1.5 – 
2.6) 
 Fib ADP 0.1µM 6.1 (3.6 – 
9.8) 
4.2 (2.9 – 9.1) 3.1 (2.7 – 10.8) 4.9 (3.4 – 
14.0) 
 Fib ADP 1µM 52.6 (41.2 – 
78) 
40.6 (31.3 – 
66.2) 
46.0 (23.9 – 
74.2) 
51.3 (43.5 
– 71.6) 
 Fib ADP 10µM 75.3 (66.9 – 
88.1) 
72.5 (60.9 – 
80.8) 
70.0 (59.7 – 
93.2) 
79.1 (70.4 
– 83.8) 
      
 P-selectin 
unstimulated 
1.5 (1.2 – 
3.0) 
2.0 (1.8 – 2.5) 2.6 (1.6 – 3.4) 1.5 (1.0 – 
3.3) 
 P-selectin ADP 
0.1µM 
3.9 (2.8 – 
7.1) 
2.7 (2.2 – 4.6) 3.9 (2.9 – 5.6) 4.9 (3.7 – 
7.7) 
 P-selectin ADP 
1µM 
47.4 (33.5 – 
67.3) 
41.9 (27.8 – 
54.8) 
47.2 (22.4 – 
60.2) 
49.2 (36.8 
– 61.4) 
 P-selectin ADP 
10µM 
74.6 (59.2 – 
81.0) 
66.1 (57.9 – 
77.5) 
74.6 (61.5 – 
85.3) 
74.1 (64.5 
– 79.6) 
      
 PMA 
unstimulated (%) 
7 (4.1 – 
15.6) 
13.8 (11.2 – 
18.3) 
11.5 (8.9 – 18.9) 10.8 (7.0 – 
14.5) 
 PMA ADP 1µM 
(%) 
17.5 (11.7 – 
34.9) 
27.1 (24.7 – 
29.5) 
26.9 (19.1 – 
32.9) 
26.8 (15.3 
– 43.7) 
      
Controls Fib unstimulated 2.1 (1.8 – 
2.7) 
3.3 (1.7 – 7.4) 2.4 (1.7 – 6.5) 2.1 (1.7 – 
4.0) 
 Fib ADP 0.1µM 5.1 (3.3 – 
8.2) 
5.8 (2.7 – 10.3) 5.9 (2.9 – 22.4) 8.5 (3.6 – 
18.3) 
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8.2) 18.3) 
 Fib ADP 1µM 59.4 (34.1 – 
70.1) 
54.8 (38.3 – 
76.4) 
62.8 (33.9 – 
78.2) 
60.0 (46.6 
– 80.2) 
 Fib ADP 10µM 80.8 (70.1 – 
87.2) 
82.0 (63.0 – 
92.0) 
81.9 (61.3 – 
91.5) 
81.0 (68.9 
– 91.6) 
      
 P-selectin 
unstimulated 
3.2 (1.8 – 
2.7) 
3.3 (2.5 – 4.4) 3.1 (1.5 – 5.0) 1.9 (1.4 – 
4.5) 
 P-selectin ADP 
0.1µM 
6.5 (3.3 – 
8.3) 
5.4 (3.1 – 6.5) 6.2 (4.1 – 13.2) 6.6 (4.6 – 
10.0) 
 P-selectin ADP 
1µM 
50.0 (39.3 – 
58.8) 
44.6 (33.0 – 
52.9) 
52.4 (32.4 – 
64.5) 
46.4 (40.0 
– 60.5) 
 P-selectin ADP 
10µM 
76.2 (64.8 – 
80.0) 
71.2 (63.8 – 
82.5) 
71.9 (61.8 – 
84.5) 
71.7 (62.8 
– 78.1) 
Fibrinogen binding and P-selectin expression on platelets’ surface (% of positive cells) were 
measured in unstimulated samples (basal activation) and in response to stimulation with ADP 1-
10µM. Data were presented as median (25th/75th centiles). All changes were not significant, P > 
0.05. T2DM, type 2 diabetes mellitus; Fib, fibrinogen binding; ADP, Adenosine 5′-diphosphate; 
PGI2, prostacyclin.  
 
 
